10th Annual Outsourcing in Clinical Trials Korea 2025

The yearly gathering for Korea’s clinical trials community to network, exchange insights, and develop partnerships that drive smarter, faster, and more efficient outsourcing strategies

2 - 3

December

2025
  • JW Marriott Dongdaemun Square Seoul
  • Ticketed
  • Why attend?
  • Agenda
  • OCT Advisory Board
  • Speakers
  • Plan Your Visit
  • Event Gallery
  • Sponsors
  • Media Centre
  • Why partner?
  • Contact Us
close

2025 Sponsors Include:

Back

Company Information

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development. With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech offers clients an accelerated path to bring life-changing therapies to market.

Company Website

To learn more, please visit our website - www.novotech-cro.com

Next Sponsor
Back

Company Information

N-SIDE is a deeptech company that empowers organizations in the life sciences to make better decisions and optimize the use of critical resources. We’re doing so by combining deep industry expertise with applied mathematics and artificial intelligence into easy to use and cutting-edge software that transforms uncertainty and complexity into deterministic outcomes. We are an active player in clinical trial supply chain management for over 20 years and have the majority of the top 20 pharmaceutical companies as clients.

With our software solution, the N-SIDE Suite, and expert services, we streamline the clinical supply of pharmaceutical and biotech companies by accelerating clinical plans, mitigating risks and curbing drug waste. We empower clinical leaders to make better, faster and safer decisions for patients waiting for life-changing medications.

Company Website

To learn more, please visit our website - https://lifesciences.n-side.com/

Next Sponsor
Back

Company Information

Akesa is an end-to-end provider of clinical trial supplies and services. Headquartered in Melbourne, Australia, Akesa boasts global reach with deep expertise in the Asia-Pacific region. We work alongside sponsors, CROs, research institutions, clinical trial sites and CDMOs to project manage the sourcing of finished products, including comparators, combination therapies, and standard-of-care medications, from validated suppliers and directly from manufacturers.

Company Website

To learn more, please visit our website - http://akesapharma.com/

Next Sponsor
Back

Company Information

360biolabs is Australia’s most comprehensive bioanalytical laboratory providing support for development of new therapeutics, vaccines and diagnostics. We support pharmacokinetic (PK) analysis, pharmacodynamic (PD) endpoints in a quality assured environment (GLP, GCP, ISO / IEC 17025). We provide the advantage of a Phase 1 solution in Australia and transfer or continuation of your clinical study with our team in the USA or Europe.

The benefits of conducting early phase clinical trials in Australia: 

  • Speed: No IND required, healthy volunteer study approval in ~4-6 weeks
  • Quality: Data recognized by global regulatory bodies (e.g. FDA, EMA)
  • Cost-Effectiveness: Up to 43.5% R&D tax incentive

Company Website

To learn more, please visit our website - http://www.360biolabs.com/

Next Sponsor
Back

Company Information

Almac Group is a global leader in providing a range of expert services and support across the drug development lifecycle.

We are trusted experts in R&D, diagnostic services, API manufacture, formulation development, clinical trial supply services and technologies through to commercial-scale manufacture and distribution.

We are recognised as an industry leader in client service, providing understanding, experience and knowledge to our clients as we work together to advance human health.

Almac is trusted by the leading global biopharma companies to provide crucial services across their drug development projects. In the last 5 years alone, we have contributed to over 50% of all FDA approved New Molecular Entities (NMEs) and are currently supporting 30% of EU approved /pre-registered Gene therapy products.

A privately owned organisation, Almac has grown organically over the past five decades, employing over 7,700 highly skilled employees across 18 facilities in Europe, North America, and Asia. Learn more about us at https://www.almacgroup.com/

Company Website

To learn more, please visit our website - https://www.almacgroup.com

Next Sponsor
Back

Company Information

BMclinical, your global clinical trial supply partner. We offer worldwide commercial medicine supply, from analytical samples to bulk comparators, through to the supply of co-meds and pre-meds.  We can pack and label your IMP/commercial medicines from our GMP facility, where we also offer storage and distribution services. BMclinical is uniquely positioned to offer solutions for overage and unused clinical trial stock.

Company Website

To learn more, please visit our website - https://www.bmclinical.com

Next Sponsor
Back

Company Information

Complex innovative clinical trial designs require a synergetic approach to assess novel drug compounds for safety and effectiveness which often span safety, regulated and esoteric outcomes in all phases of the drug development life cycle. The companies of Eurofins Bioanalytical Services, the Eurofins Central Laboratory global network, Eurofins Viracor BioPharma Services, and Eurofins Clinical Trial Supplies are strongly connected to provide a solutions-based approach to our client needs.  Eurofins Clinical Trial Solutions provides seamless, end-to-end solutions to help clients progress through the drug development cycle through a single, experienced provider. Our solutions deliver the most comprehensive range of state-of-the-art analytical technologies with an extensive geographic reach to support our clients’ testing and clinical supplies needs and stringent quality and safety requirements around the world.

Company Website

To learn more, please visit our website - https://www.eurofins.com/biopharma-services/clinical-trial-solutions/

Next Sponsor
Back

Company Information

George Clinical is a leading CRO in Asia Pacific, with unparalleled Investigator networks. Since 1999, we have been providing full trial management services to biopharmaceutical customers. George Clinical combines

Company Website

To learn more, please visit our website - www.georgeclinical.com

Next Sponsor
Back

Company Information

Scout empowers the life sciences industry with people-first solutions: Scout Meetings, Scout Clinical, and Scout Academy. We specialize in face-to-face, virtual, and hybrid clinical meeting planning, patient payment, travel, and logistics support, and virtual collaboration and education. Since 1995, we have been a trusted partner excelling in customer service, regulatory compliance, and project delivery for leading pharmaceutical and biotechnology companies. Our deep understanding of international regulations and adaptable network of resources is built on operational experience in 109 countries. With white-glove attention to detail and a customizable, comprehensive range of services, Scout makes the complex easier. Learn more at scoutclinical.com.

Next Sponsor
Back

Company Information

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,000 people across 44 countries.

Company Website

To learn more, please visit our website - http://www.medpace.com/

Next Sponsor
Back

Company Information

Euromed Pharma deliver strategic services tailored to support companies in their quest to better healthcare. We support each industry player from drug development through the post-marketing phases. We offer solutions in CTS services, Clinical GMP Packaging, Labeling and Distribution, IMP management, Early Access and Named Patient Programs, Pharma Order to cash solutions, and Supply Chain & Logistics. We are present around the world with offices in Italy, Spain, Ireland, Germany, Singapore and the USA. Being one of the Petrone Group companies, Euromed Pharma is positioned at the forefront of innovation in pharmaceutical distribution.

Company Website

To learn more, please visit our website - www.euromed-pharma.com

Next Sponsor
Back

Company Information

QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. We are passionate about our work, creating value for patients and customers while generating opportunities for employees to thrive.

Company Website

To learn more, please visit our website - www.qps.com

Next Sponsor

    Why attend?

    The leading  Outsourcing in clinical trials conference in Korea is returning in 2025. With a focus on providing delegates with practical take-aways and solutions to their most current operational and outsourcing challenges in clinical trials, this is an event not to be missed.

    Why join?

    Unlike other conferences, our event focuses especially on the regional pharmaceutical business in Asia, highlighting the industry’s current difficulties as well as its exciting innovations and growth prospects.

     

    Not only will the audience be discussing clinical partnership and supply challenges, but we also have the Clinical Trial Supply Korea conference co-located with the event to give you the opportunity to define an end-to-end clinical strategy.

    Meet and network with over 250 senior industry decision makers during our dedicated networking breaks, round tables and interactive sessions.

    Agenda

    • 2 Dec 2025
    • 3 Dec 2025
    Expand All

    8 AM

    Registration and refreshments

    8:40 AM

    Chairperson’s opening remarks

    8:45 AM

    How to Choose the Right Clinical CRO: A Strategic Guide for Biotech Venture

    • Determining the optimal stage for CRO engagement to maximize efficiency
    • Engaging CROs in protocol development to inform strategic decisions, including country selection and trial design considerations
    • Leveraging CRO expertise by fostering a collaborative, partnership-driven relationship

    Speakers

    Sol Han
    Chief Medical Officer, Head of Clinical Development Center, Cyrus Therapeutics

    9:15 AM

    Reserved for Novotech

    9:45 AM

    KEY NOTE: Why Listening to Patients Matters: Redefining Clinical Development Strategies

    • Understanding how prioritizing patient care enhances trial success
    • FDA guidance driving patient-centric clinical development
    • Real-world impact of patient input on protocol design and trial conduct

    Speakers

    Kazuhiko Takahata
    Senior Director, Head of Clinical Development Group 3, Clinical Development Centre, Kyowa Kirin(Japan)

    10:15 AM

    Reserved for the Event Partner

    10:45 AM

    Morning refreshments and networking

    11:30 AM

    From Hurdles to Insights: Navigating Early-Stage Clinical Trials

    ·        Addressing common operational and scientific challenges in Phase 1 and Phase 2 trials

    ·        Managing complex protocol designs incorporating biomarkers and adaptive trial elements

    ·        Evaluating the necessity of placebo groups in Phase 1 studies

    Speakers

    Choong Hee LEE
    Director, Clinical Development, Vasthera

    12 PM

    Reserved for Nucleus Network

    12:30 PM

    Patient Access in Clinical Trials : Global Trends and What It Means to South Korea

    ·       Global Trends in Patient Access

    ·       Eli Lilly’s Approach

    ·       Local Efforts to Improve Patient Access

    Speakers

    Heewon Lee
    Manager, Clinical Research Lead, Eli Lilly

    1 PM

    Lunch and networking

    2:15 PM

    Developing a Clinical Oversight Strategy Using Big Data and BI Tools

    ·        Enhancing oversight of CROs, vendors, and trial sites through centralized data insights

    ·        Utilizing Business Intelligence (BI) tools to visualize trial health in real time

    ·        Case examples of effective use of BI tools in optimizing clinical timelines, cost, and compliance

    Speakers

    Jongyeop (Peter) Kim
    Lead Manager, Big Data Team, Daewon pharmaceutical

    2:45 PM

    Empowering Biotechs in Asia: The Strategic Role of CROs for Korean and Regional Sponsors

    • Supporting Korean Biotechs in Global Expansion: How CROs provide Korean sponsors with the regulatory navigation, operational readiness, and site access needed to move beyond domestic trials into global markets.
    • CRO-Enabled Asia Hub: Lessons from Avance Clinical in establishing entities, vendor networks, and site collaborations across Asia — with Korea and Taiwan as foundation hubs — to provide biotechs with turnkey infrastructure.
    • From Early Phase to Multiregional Trials: How CRO partnerships connect Australia’s fast Phase I ecosystem with Asia’s Phase II/III scale, enabling Korean and Asian biotechs to accelerate global development pathways

    Speakers

    Jessica (Youngji) Han
    Jessica (Youngji) Han, Director, Asian Operations, Avance Clinical

    3:15 PM

    CASE STUDY: Optimizing T Cell Engaging Therapies from Preclinical Study to Human Clinical Trial: Conditional Activation of T Cell in the Tumor Microenvironment by a Novel 4-1BB T Cell Engaging BsAb (Grabody T)

    ·       The Grabody T platform: A Clinically Validated 4-1BB Bispecific Antibody Approach to Overcome Liver Toxicity

    ·       Grabody T Exhibits TAA-Dependent 4-1BB Activation and Strong in vivo Efficacy

    ·       Promising Clinical Activity and Favourable Safety Profile Across the Grabody T Pipeline (Givastomig, Ragistomig, and YH32367)

    Speakers

    Sangmi Lee
    Head of Clinical Development, ABL Bio

    3:45 PM

    Afternoon refreshments and networking

    4:15 PM

    KEY NOTE: Driving CRO Performance in Clinical Trial

    • Determining the optimal stage for CRO engagement to maximize efficiency
    • Engaging CROs in protocol development to inform strategic decisions, including country selection and trial design considerations
    • Leveraging CRO expertise by fostering a collaborative, partnership-driven relationship

    Speakers

    Eunah Paek
    Executive Director, Boryung corporation

    4:45 PM

    PANEL DISCUSSION: Staying Ahead of the Curve: Key Trends Transforming Clinical Trials

    • Advancing trial efficiency through AI, automation, and digital platform integration
    • Exploring emerging trends and innovations in clinical trial research and design
    • Assessing data-driven strategies to improve patient centric outcomes and value in trials

    Speakers

    Sangwoo Lee
    CEO, Jeju Biotek
    Kazuhiko Takahata
    Senior Director, Head of Clinical Development Group 3, Clinical Development Centre, Kyowa Kirin(Japan)

    5:15 PM

    Chairperson’s closing remarks

    8:15 AM

    Registration and refreshments

    8:50 AM

    Chairperson’s opening remarks

    9 AM

    Strategic Implementation of AI to Accelerate Drug Development and Optimize Clinical Trials

    • Leveraging AI-driven approaches such as virtual screening and molecular docking
    • Utilizing machine learning models to predict biological activity and accelerate lead compound optimization
    • harnessing AI to design agile and data-driven trial protocols

    Speakers

    Amy Jung Hyun LEE
    Medical imaging expert

    9:30 AM

    Bridging Borders and Regulations: QPS Perspectives on U.S. FDA and APAC Alignment

    • Regulatory landscape US Pre-IND and IND
    • Bridging APAC With US
    • Current US Administration /FDA- What are we seeing at QPS

    Speakers

    Derek Grimes
    EVP, Global Clinical Research, QPS Holdings, LLC

    10 AM

    KEY NOTE: Evolving Clinical Trial Designs: Key Considerations and Best Practices for Implementing Decentralized Clinical Trials (DCT)

    • Key considerations for planning and determining the suitability of DCTs
    • Reviewing how DCTs can enhance trial reach and significantly boost patient recruitment
    • Sharing practical insights and lessons learned from implementing DCTs

    Speakers

    Tina Sun
    Tina Sun, SSO, Country Head, Novartis (Taiwan); President, TCRA (Taiwan Clinical Research Association)

    10:30 AM

    Reserved for IROS

    11 AM

    Morning refreshments and networking

    11:45 AM

    Strategic Considerations for Clinical Trials in Cell Therapy Development

    • Addressing regulatory uncertainties and evolving guidance for advanced therapies
    • Building trial plans that embed real-world evidence and extended follow-up
    • Implementing robust safety monitoring strategies for acute and long term risks

    Speakers

    YOHAN BAE
    Executive Director, Clinical Development Division, Kangstem Biotech

    12:15 PM

    PANEL DISCUSSION: Overview of Clinical Trial Dynamics Affecting Small to Mid-Sized Biopharma in Korea

    • Current landscape and growth trends of clinical trials in Korea, especially for small/mid-sized biopharma
    • Navigating the evolving vendor and CRO ecosystem as a small to mid-sized sponsor
    • Regulatory environment and recent updates impacting trial initiation and approvals

    Speakers

    Sangwoo Lee
    CEO, Jeju Biotek
    Tina Sun
    Tina Sun, SSO, Country Head, Novartis (Taiwan); President, TCRA (Taiwan Clinical Research Association)
    YOHAN BAE
    Executive Director, Clinical Development Division, Kangstem Biotech

    1 PM

    Lunch and networking

    Prize Draw taking place in exhibition hall at 14:15

    Join us for a chance to win one of our prizes, including Apple products

    2:30 PM

    Unlocking FDA Strategies for Speedy Approval and Smart Dosing in Oncology Trials

    • Exploring recent US FDA updates on expedited approval pathways and dosing strategies in oncology
    • Designing clinical trials that meet FDA expectations for surrogate endpoints and biomarker use
    • Developing regulatory-aligned strategies for oncology drug development under new FDA guidance

    Speakers

    Young Su (Bobby) Noh
    Director, Head of Clinical Research and Development (ONCO),Hanmi Pharm

    3 PM

    Speaker Hosted Roundtables

    Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

    Roundtable session lasts for 30 minutes and rotate

    ROUNDTABLE 1: Comparator Sourcing in Small Biotech: Overcoming Limits with Strategic Outsourcing

    ROUNDTABLE 2: Driving Efficiency and Results Through Strong Sponsor, CRO Partnerships

    YongGwan Kim, Associate Director, Janssen

    ROUNDTABLE 3: Key Areas to Focus on for Proactive Inspection Preparedness in Today’s Regulatory Landscape

    ROUNDTABLE 4: Integrating Packaging and Labeling with Clinical Supply Chain Operations

    Speakers

    YongGwan Kim
    Associate Director, Janssen

    3:30 PM

    Chairperson’s closing remarks

    END OF CONFERENCE

    Speakers

    Select a speaker to learn more

    Back
    Priya Ravisekara
    Senior Pharma Analyst, GlobalData Plc

    Priya Ravisekara, MSc,is a senior analyst at GlobalData in London, UK, where her primary responsibilities include producing analytical reports, improving and maintaining database functionality through quality assurance testing, updating and monitoring Global Data’s Clinical Trials Intelligence Database, and answering queries directly from clients. Priya holds a Masters in Clinical Drug Development from Barts and The London School of Medicine and Dentistry, and a Bachelor of Science in Biochemistry from Brunel University, London.​

    Next speaker
    Back
    Sangwoo Lee
    CEO, Jeju Biotek

    With 16 years of experience in the pharmaceutical industry, including over 5 years in non-clinical pharmacology and nearly a decade in clinical development, Sangwoo Lee has managed more than 10 clinical studies across both international sites (United States, Australia, Indonesia, and Singapore) and domestic settings in South Korea.

    Specialties

    Full Scoped Clinical Development

    Clinical trial operation management and supervision based on Regulations and ICH guidelines

    Development of IND CTD module relevant for Clinical Trial and Nonclinical Study

    Planning and Management of Clinical Study Timeline and Budget

    Vendor Selection and Management (CRO, Analytical Lab, Couriers)

    Study Site Management and communication

    IMP Management (Blinded)

    Session Details:

    PANEL DISCUSSION: Staying Ahead of the Curve: Key Trends Transforming Clinical Trials

    2025-12-02, 4:45 PM

    Session Details:

    PANEL DISCUSSION: Overview of Clinical Trial Dynamics Affecting Small to Mid-Sized Biopharma in Korea

    2025-12-03, 12:15 PM

    View In Agenda
    Next speaker
    Back
    Young Su (Bobby) Noh
    Director, Head of Clinical Research and Development (ONCO),Hanmi Pharm

    Young Su (Bobby) Noh, Ph.D., is the Director, Clinical Research and Development (Oncology), Hanmi Pharma and a representative of IFPMA, ICH E22 informal Expert Working Group. Dr. Noh is also working as a committee member of KIC2025, an external Instructor in KoNECT and a reviewer of external evaluation committee of KDDF. Dr. Noh has been responsible for leading clinical program with NMEs or NBEs in multi-therapeutic area: including metabolic diseases and rare diseases as well as oncology and hematology for 17 years. Dr. Noh has a lot of experience for collaborating with global big pharma as well as biotech companies.

    Previously, Dr. Noh served as an adjunct professor, department of regulatory science for Kyung Hee university and an expert, several guidelines Working Group of MFDS. Dr. Noh received his Ph.D. in pharmacy Kyung Hee University.

    Session Details:

    Unlocking FDA Strategies for Speedy Approval and Smart Dosing in Oncology Trials

    2025-12-03, 2:30 PM

    View In Agenda
    Next speaker
    Back
    Kazuhiko Takahata
    Senior Director, Head of Clinical Development Group 3, Clinical Development Centre, Kyowa Kirin(Japan)

    Experienced clinical development leader with a proven record in strategic decision-making and cross-functional team leadership within global pharmaceutical organizations.

    Expertise spans immunology, oncology, and allergy therapeutic areas, with deep experience in cross-border regulatory engagement and clinical trial execution.

    Combines scientific rigor with a business-focused mindset, currently pursuing a PhD in health economics to further strengthen academic and strategic capabilities.

    Session Details:

    PANEL DISCUSSION: Staying Ahead of the Curve: Key Trends Transforming Clinical Trials

    2025-12-02, 4:45 PM

    Session Details:

    KEY NOTE: Why Listening to Patients Matters: Redefining Clinical Development Strategies

    2025-12-02, 9:45 AM

    View In Agenda
    Next speaker
    Back
    Jongyeop (Peter) Kim
    Lead Manager, Big Data Team, Daewon pharmaceutical

    Education: Department of Business, Tourism and Accounting, Major in Business Administration, Kangwon National University

    Career: Daewon Pharmaceutical Co Ltd (Medical Representative - Distribution Manager - Sales Planner - Big Data Specialist)

    Session Details:

    Developing a Clinical Oversight Strategy Using Big Data and BI Tools

    2025-12-02, 2:15 PM

    View In Agenda
    Next speaker
    Back
    YOHAN BAE
    Executive Director, Clinical Development Division, Kangstem Biotech

    Yohan Bae is Executive Director, Clinical Development Division at Kangstem Biotech Co. Ltd since he joined in Mar 2020. He has almost 30 years of drug development experience ranging local and global regulatory affairs, clinical development, and patient access for pharmaceutical and medical device. Before he joined in Kangstem Biotech, Mr. Bae has worked for large international pharma and medical device companies such as Alcon, Bristol-Myer Squibb, and Boehringer-Ingelheim. He holds a master’s degree in Pharmacology from Pharmacy College, Kyunghee University.

    Session Details:

    Strategic Considerations for Clinical Trials in Cell Therapy Development

    2025-12-03, 11:45 AM

    Session Details:

    PANEL DISCUSSION: Overview of Clinical Trial Dynamics Affecting Small to Mid-Sized Biopharma in Korea

    2025-12-03, 12:15 PM

    View In Agenda
    Next speaker
    Back
    Eunah Paek
    Executive Director, Boryung corporation

    Ms. Eun-Ah Paek, Executive Director at Boryung Co., Ltd., majored in Pharmacy at Sookmyung Women’s University, where she also earned her Master’s degree in Pharmacology. She subsequently completed her doctoral coursework in Pharmacoepidemiology at Sungkyunkwan University.

    She previously served as a project leader for central nervous system (CNS) drug development at SK Biopharm and is currently in charge of clinical trials, post-marketing clinical research, pharmacovigilance, and medical writing as the head of the Clinical Division at Boryung.

    With over 30 years of experience, she has been involved in comprehensive drug development, spanning from non-clinical research to clinical trials and post-marketing activities for pharmaceuticals.

    Session Details:

    KEY NOTE: Driving CRO Performance in Clinical Trial

    2025-12-02, 4:15 PM

    View In Agenda
    Next speaker
    Back
    Choong Hee LEE
    Director, Clinical Development, Vasthera

    Session Details:

    From Hurdles to Insights: Navigating Early-Stage Clinical Trials

    2025-12-02, 11:30 AM

    View In Agenda
    Next speaker
    Back
    Amy Jung Hyun LEE
    Medical imaging expert

    Amy is a seasoned imaging clinical trial expert with a PhD in Biomedical Sciences and extensive experience in the design, execution, and evaluation of imaging across multiple therapeutic areas, including oncology, ophthalmology, neurology, dermatology, musculoskeletal, and gastroenterology. With nearly a decade of leadership in managing imaging projects, she has worked with global pharmaceutical companies, leading CROs, and major hospitals worldwide. Her career journey spans roles from imaging project manager to CEO of a Singapore-based imaging CRO, and she now brings her expertise to a global imaging CRO.

    Session Details:

    Strategic Implementation of AI to Accelerate Drug Development and Optimize Clinical Trials

    2025-12-03, 9:00 AM

    View In Agenda
    Next speaker
    Back
    Jaeyoung Hyun
    Unit Manager, GCCL

    Jaeyoung Hyun serves as Head of the Business Development Unit at GCCL(Global Clinical Central Lab), a leading central lab in Asia Pacific specializing in clinical trial sample analysis for global pharmaceutical and biotech sponsors. In this role, he oversees domestic and global client engagement, strategic sales, and partnership development, driving GCCL’s growth and international presence.

    With a long-standing career in domestic sales and business development within the pharmaceutical and healthcare industries, Mr. Hyun has cultivated deep expertise in fostering client relationships, shaping commercial strategies, and supporting multinational clinical programs. His professional background includes extensive collaboration with pharma and biotech companies, with a focus on overcoming logistical barriers in clinical sample management—an area he will address in his OCT Korea 2025 session, “Optimizing Central Lab Supply Chains: Overcoming Logistical Barriers in Clinical Sample Management.”

    Next speaker
    Back
    Seunghyun Hong
    Logistics Manager, GCBiopharma
    Next speaker
    Back
    Sangho Ma
    VP Development , A&J science

    Dr. Sang Ho Ma, Ph.D. in Pharmacy, is Vice President of Development at A&J Science and a member of the Expert Committee of the Ministry of Food and Drug Safety (MFDS). With over 20 years of

    experience in drug discovery and development, including CMC, regulatory affairs, and clinical research, he provides expertise across immuno-oncology, rare diseases, infectious diseases, and vaccines.

    Next speaker
    Back
    Sol Han
    Chief Medical Officer, Head of Clinical Development Center, Cyrus Therapeutics
    Sol Han currently serves as the Chief Medical Officer (CMO) and Head of Clinical Development at Cyrus Therapeutics, a company specializing in oncology drug development. In this pivotal role, Sol is spearheading critical phases of drug development, including Investigational New Drug (IND) application submissions, early-stage clinical development, and the successful translational research that bridges non-clinical findings to human clinical trials.
    With a professional background in pharmacy at Ewha Woman’s University, Sol brings two decades of deep industry experience, including 15 years garnered at Global Big Pharma companies such as Roche, GSK, and Sanofi. During this tenure, Sol established a distinguished clinical professional career as a Global Leader, successfully pioneering clinical operations and development not only locally but also globally.
    Leveraging this profound expertise gained within the patient-centric and trend-setting global pharmaceutical landscape, Sol is now at Cyrus Therapeutics, successfully integrating advanced clinical development know-how into the domestic biotech sector and proactively elevating the company's clinical capabilities to a global standard.

    Session Details:

    How to Choose the Right Clinical CRO: A Strategic Guide for Biotech Venture

    2025-12-02, 8:45 AM

    View In Agenda
    Next speaker
    Back
    YongGwan Kim
    Associate Director, Janssen
    • Associate Director-Trial Delivery Leader, Medical Affairs Delivery Unit, J&J Innovative Medicine
    • Masters Degree of Supply Chain Management, MBA, Inha University

    Session Details:

    Speaker Hosted Roundtables

    2025-12-03, 3:00 PM

    View In Agenda
    Next speaker
    Back
    Alicia Kim
    Clinical Trials Team Leader, LN Robotics

    - 23Y Clinical Trial & New Drug Development Expert Professional

    - Global & Local Trials Experiences including the 1st Phase 2 COVID-19 New Oral-drug Trial PM in Korea & USA

    - Global CROs and Local Pharmacies Experiences

    - All-round Experts in Clinical Trials (Medicines & Devices)

    Next speaker
    Back
    HyeJung Yang
    Clinical Development Center, Clinical Team Lead, Daewoong Pharmaceutical

    Hyejung Yang is the Team Leader of the Clinical New Drug Team at Daewoong Pharmaceutical. She has over 14 years of experience in global clinical development, leading Phase I–III trials across multiple therapeutic areas, with a particular focus on new drug development projects. She has extensive expertise in project leadership, study start-up, investigational product management, and global site/vendor communication. As a clinical team leader, she has directed cross-functional teams and contributed to IND submissions, ensuring successful execution of global clinical trials.

    Next speaker
    Back
    Tina Sun
    Tina Sun, SSO, Country Head, Novartis (Taiwan); President, TCRA (Taiwan Clinical Research Association)

    With over 20 years of experience in clinical operations, Tina held leadership positions at Eli Lilly and Novartis, managing operations in Taiwan and Hong Kong. Besides her corporate roles, she led Transcelerate Taiwan since 2013 and served twice as the president of the Taiwan Clinical Research Association. Tina is interested in external engagement activities through her journey in clinical operations. Her authority in the field is demonstrated further through speaker roles at universities, conferences and clinical trial training programs, particularly on GCP-related topics.

    Specialties

    Global clinical trials operations and management

    Speaker of clinical trial topics in GCP training program, university and conference

    Professional Experiences

    Trial Monitoring Country Head, Novartis (Taiwan)

    Head of Clinical Operations, Eli Lilly and Company (Taiwan & Hong Kong)

    President of Taiwan Clinical Research Association (5th ,TCRA)

    Medical representative, clinical research associate, Novartis (Taiwan)

    Pharmacist, Po-Ai Hospital

    Session Details:

    KEY NOTE: Evolving Clinical Trial Designs: Key Considerations and Best Practices for Implementing Decentralized Clinical Trials (DCT)

    2025-12-03, 10:00 AM

    Session Details:

    PANEL DISCUSSION: Overview of Clinical Trial Dynamics Affecting Small to Mid-Sized Biopharma in Korea

    2025-12-03, 12:15 PM

    View In Agenda
    Next speaker
    Back
    Hyesung Shin
    Director, Clinical Development Strategy, R&D Division, Aptabio

    Hyesung Shin, managing director of TiumBio Co., Ltd has worked more than 23 years of experience in clinical trial development and operations.

    She had worked during 13 years for global pharmaceutical companies at Eli Lilly, Novo Nordisk and Novartis and 6 years at Abbott for medical devices clinical development and had experienced in Korean Biotech companies of BioPharm Solutions, Aptabio Therapeutics, TiumBio for new drug development and managing phase I/II Clinical Trial.

    The works focused on managing clinical trial plan for new drug development, regulatory Filing for FDA/EMEA/MFDS IND, orphan drug Designation, vender management including CRO/Clinical Supplies/CDMO and development of  market strategy.

    Next speaker
    Back
    Jungwon Jung
    Production Team2 Manager , HK inno-N

    -1997 ~ 1999        :  KATRI (Korea apparel test and research institute)
    - 2000 ~ 2001        :  Green Cross     

    - 2001 ~ Present   :  HK inno-N. (old CJ Healthcare)

    * 2001 ~ 2010 Quality Assurance Team

    * 2010 ~ 2015 Technical development Team

    * 2015 ~ 2017 Quality Manager

    * 2017 ~ 2019 Project TF team (Head office) for New Plan & Bio Project

    * 2019 ~ 2022 Quality Unit Manager (Cell and Gene Therapy Plant

    * 2022 ~          Manufacturing2 Team Manager (LVP)

    Next speaker
    Back
    Sangmi Lee
    Head of Clinical Development, ABL Bio

    A seasoned leader with over two decades of experience in clinical development, Sangmi Lee is currently the Head of Clinical Development at ABL Bio Inc., where she spearheads the company's oncology pipeline. Her extensive career spans both global and local pharmaceutical landscapes, including leadership roles at Novartis, Chong Kun Dang, and GreenCross.

    Specializing in early-stage development, Sangmi Lee has deep expertise in advancing complex therapeutic modalities, with a particular focus on T-cell engagers, bispecific antibodies, and bispecific ADCs. Her presentation, "Optimizing T Cell Engaging Therapies from Preclinical Study to Human Clinical Trial," will draw on her comprehensive background in translating cutting-edge science into successful human clinical trials.

    Session Details:

    CASE STUDY: Optimizing T Cell Engaging Therapies from Preclinical Study to Human Clinical Trial: Conditional Activation of T Cell in the Tumor Microenvironment by a Novel 4-1BB T Cell Engaging BsAb (Grabody T)

    2025-12-02, 3:15 PM

    View In Agenda
    Next speaker
    Back
    Jeffery Wong
    Senior Director of Business Development, Nucleus Network

    Jeffery Wong is the Senior Director of Business Development at Nucleus Network, one of the world’s largest Phase I Clinical Trial Service provider with operations spreading across both Australia and the USA.

    A strong business development professional, Jeffery graduated from RMIT University, holds a Masters in Business and Biotechnology with a major in Pharmaceutical Sciences. During his 18 years with Nucleus Network, Jeffery has seen the growth of Nucleus Network from a 24 bed not for profit organisation to its current capacity of over 200 phase I beds spread across the globe.

    Jeffery has a passion in supporting industry members to achieve their clinical development goals and leverages on his extensive knowledge in business development, project operation, clinical study design and regulatory affairs.

    Next speaker
    Back
    Jessica (Youngji) Han
    Jessica (Youngji) Han, Director, Asian Operations, Avance Clinical
    Jessica (Youngji) Han has over 18 years of experience in the healthcare and clinical research industry, with strong expertise in clinical operations, project management, and regulatory strategy.
    At Avance Clinical, Jessica oversees the development of a robust operational platform across Asia, integrating clinical delivery excellence, regulatory expertise, and local partnerships. Her leadership ensures that biotech sponsors can conduct high-quality, efficient, and compliant clinical trials tailored to the unique dynamics of the APAC region.
    Avance Clinical has been instrumental in advancing its GlobalReady Pathway, which connects Australia’s early-phase ecosystem with Asia’s scalability — accelerating global drug development for innovative biotech companies.
    Jessica’s strategic focus and operational insight position Avance Clinical as a trusted partner for biotechs seeking to leverage Asia’s diverse patient populations and world-class research infrastructure to achieve their clinical development goals efficiently.

    Session Details:

    Empowering Biotechs in Asia: The Strategic Role of CROs for Korean and Regional Sponsors

    2025-12-02, 2:45 PM

    View In Agenda
    Next speaker
    Back
    Derek Grimes
    EVP, Global Clinical Research, QPS Holdings, LLC

    Derek Grimes is the Executive Vice President of Global Clinical Research at QPS Holdings, LLC, where he leads global Phase I–IV clinical operations and strategic partnerships. With over two decades of experience in clinical research, Derek has built and managed large-scale programs across the US, Europe, and APAC, specializing in oncology and early-phase drug development. Before joining QPS, he held senior leadership roles in academic and industry settings, where he focused on operational excellence, innovation in clinical trial execution, and global regulatory strategy. Derek is passionate about bridging US and APAC clinical research ecosystems to accelerate global drug development.

    Session Details:

    Bridging Borders and Regulations: QPS Perspectives on U.S. FDA and APAC Alignment

    2025-12-03, 9:30 AM

    View In Agenda
    Next speaker
    Back
    Anna Park
    Industry Affairs Manager, International Air Transport Association (IATA)

    Anna Park is the Industry Affairs Manager at the International Air Transport Association (IATA). She is based at the country office of the Republic of Korea in Seoul.
    IATA is the trade association for the world’s airlines, representing some 300 airlines or 83% of total air traffic. IATA supports many areas of aviation activity and helps formulate industry policy on critical aviation issues. In her role, Anna looks after industry advocacy affairs, IATA’s product and service delivery to Air Cargo dedicated to certification, digitalization (One Record), and data solutions, as well as Customer Experience such as One ID initiative in the Korean market.
    A key focus of her portfolio is supporting member airlines and aviation stakeholders in promoting global standards and practical solutions that enhance air cargo operations such as CEIV Pharma certification and the implementation of IATA guidelines that strengthen quality and compliance across the cargo supply chain. Anna has enriched experience over 17 years in the aviation industry including a 9-year stint at their Asia-Pacific regional office in Singapore and has been with IATA since 2008

    Next speaker
    Back
    Heewon Lee
    Manager, Clinical Research Lead, Eli Lilly

    Heewon Lee is a Clinical Research Lead at Eli Lilly, responsible for leading the initiation and operation execution of clinical trials for Lilly molecules. Her work focuses on country feasibility, site selection, and investigator engagement. She has over 12 years of experience in the pharmaceutical industry brings deep expertise in clinical operations.

    Session Details:

    Patient Access in Clinical Trials : Global Trends and What It Means to South Korea

    2025-12-02, 12:30 PM

    View In Agenda
    Next speaker

    OCT Advisory Board

    Select a member to learn more

    Back
    Dr Alison McMorn
    PH.D – VP, CLINICAL DEVELOPMENT, AMO PHARMA LTD

    Dr. McMorn is an experienced clinical development researcher with over 25 years of industry experience and has a strong focus in CNS and paediatric drug development. She has worked for both Pharmaceutical Companies and Contract Research Organisations including holding positions at SAR Monitoring Services Ltd, Mundipharma International Ltd and Shire Development Inc. Starting her career at SAR as a Clinical Research Associate (CRA) she subsequently moved to Mundipharma where she was responsible for initiating the first paediatric clinical research program for the company. At Shire Dr. McMorn led, planned and managed global paediatric and adult clinical development programs for a wide variety of indications including psychiatry, pain, gastrointestinal and hepatology across all phases of development (Phase 0 to Phase 4). In addition she was responsible for harmonizing Clinical Trial Administrator (CTA) working practices across all regions for the company. In 2015 Dr. McMorn joined AMO Pharma Ltd, a virtual pharmaceutical company focused predominantly on paediatric neurodevelopmental rare diseases, as VP of Clinical Development. She holds an undergraduate degree in Pharmacology and a PhD in Psychology from the University of Leeds, UK.

    Next
    Back
    Behtash Bahador
    Senior Director, Community Engagement & Partnerships, CISCRP

    Behtash Bahador is the Senior Director of Community Engagement & Partnerships at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.

    Next
    Back
    Kathleen Cohen
    Vice President, Clinical Development, Marinus Pharmaceuticals

    Kathleen Frenia Cohen is Vice President and Head of Clinical Development Operations at Marinus Pharmaceuticals.  Prior to joining Marinus, she spent 20+ years at PRA Health Sciences in a variety of project management and operational oversite roles. Kathleen graduated from the University of the Science in Philadelphia with a PharmD and completed a post-doctoral fellowship in Pharmacoeconomics and Outcomes Research from Rutgers College of Pharmacy. Kathleen resides in Media, PA.

    Next
    Back
    Aditya Kotta
    Head of Business Development, Novotech

    Aditya is the Regional Director of Business Development at Novotech, the Asia Pacific specialist CRO. He has extensive experience helping sponsor companies make their trials a reality across a range of projects from first in human to phase iv.

    Next
    Back
    Martin Rodriguez
    Consumer Safety & Evidence Global Quality & Excellence Head, Sanofi

    Senior executive Leader in Life Science (Biochemist) and Lean/Six Sigma Green-belt certified, with more than 20 year of experience in clinical operations, Operational Excellence (i.e., operational strategy, performance management, process optimization, risk management, Quality-by-Design and team performance), clinical quality, and Service Providers / Outsourcing management.

    I developed, reengineered, automated, and optimized business processes with a risk-based and approach to produce high quality outputs and to ensure regulatory compliance. I led the development, implementation and monitoring of different operational and quality strategies and models including Outsourcing as well as new/ innovative clinical capabilities to fulfill consumers/ patients needs .

    Next
    Back
    Rosalie Filling
    Vice President, Senior Global Head R&D Operations, Endo Pharmaceuticals

    In her over 25 years of experience, Rosalie “Rosie” Filling has transformed R&D operations in every company she has worked for, developing clear-cut strategies to help advance clinical trials with high-quality operational execution and scientific excellence.

     

    Rosie is the Vice President, Senior Global Head R&D Operations Endo International plc. She is part of the global R&D leadership team and is charged with the coordination and implementation of clinical development strategies for the company’s research and development. She provides strategic direction and oversight of the R&D Operations team, which includes clinical operations, data management, biostatistics, medical writing, clinical supplies, trial master file/inspection readiness and business operations. This integrated team handles the execution of all aspects related to Endo’s clinical trials. Endo has active research and development programs in men’s health, orthopedics, and endocrinology. Beyond these therapeutic areas, the company also has focused development in the areas of sterile injectables and complex generic products.

     

    Rosie’s main focus at all times is on the end users—the patients. Bringing new and, at times, life-saving medications to patients drives Rosie’s sense of purpose.

     

    Rosie joined Endo from Lupin Pharmaceuticals in Blue Bell, PA where she was Senior Director, Head of Clinical Operations, and built the clinical operations organization to support the US and Global R&D Organization. Prior to Lupin, Rosie spent nearly five years at Teva in Frazer, PA where she was the US site head of Clinical Operations and was responsible for the successful delivery of Inhalation, Women’s Health, and Cardiovascular clinical trials. Earlier in her career, Rosie held various roles at Eisai, MGI Pharma and PPD.

     

    Rosie earned her B.S. in Biology with a minor in Chemistry from the University of Pittsburgh.

    Next
    Back
    Edwin van Vulpen
    Executive Director and Head of Clinical Business Development Euro-Asia
    Next

    Plan Your Visit

    JW Marriott Dongdaemun Square Seoul

    279, Cheonggyecheon-ro, Jongno-gu Seoul, South Korea, 03198

    Book Your Stay

    Outsourcing in Clinical Trials & Clinical Trial Supply Korea discounted room rate - KRW360,000 (excl. tax, breakfast an additional KRW30,000)

    Arena International Events Group “(Arena”) is aware of numerous third-party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings, events attendee lists and selling unsolicited services. It is unclear whether the agencies in question are in possession of such information, or whether they intend to scam unsuspecting customers. Whilst Arena International Events Group pursues such third-party companies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third-party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group..

    Sponsors

    Select a sponsor to learn more

    Featured Sponsor

    Session Sponsor

    Exhibitors

    Co-Sponsor

    Why partner?

     

    Contact us to become a partner

    Partnership Opportunities

    We work with you to design a bespoke package to meet your business needs, where you could:

    • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
    • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
      Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
    • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

    Event reach

    • 250+ attendees each year
    • 80% attendees C-suite level

     

    Take a look at our current sponsors

    Media Centre

    Become A Media Partner

    Enquiry

    Contact Us

    SPONSORSHIP ENQUIRIES

    Nicholas McCudden

    Head of OCT Events

    +61 280 978 126

    SPEAKER ENQUIRIES

    Ranhee Yoo

    Conference Producer

    +44 207947 2793

    MARKETING ENQUIRIES

    Maya Hudson

    Head of Production

    DELEGATE ENQUIRIES

    Sunny Saikia

    VIP Delegate Manager

    Sponsorship Enquiries

    To enquire about sponsorship opportunities for the conference, please contact:

    Nicholas McCudden

    Head of OCT Events


    +61 280 978 126

    Speaker Enquiries

    To enquire about speaking opportunities for the conference, please contact:

    Ranhee Yoo

    Conference Producer


    +44 207947 2793